SBIR Phase II: Multiplex Expansion of the Chiral Carbon Catalog Platform towards Stereo-enriched Non-propionate Chemical Classes and Industrial Applications
Award amount
$949,999Program and phase
SBIR · Phase IIAward year
2020Award details
- Awarding agency
- National Science Foundation
- Branch
- Not reported
- Recipient company
- AKANOCURE PHARMACEUTICALS INC
- Proposal award date
- 2020-04-01
- Contract end date
- 2022-03-31
- UEI
- QMU8ZFLN2A34
- Solicitation number
- Not reported
- Topic code
- CT
Research abstract
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- SBIR Phase II: A Novel Host-Directed Broad-Spectrum Antiviral and Efficient Immunomodulatory Agent Against Coronaviruses: Lead Optimization Studies
- SBIR Phase I: AK-423: A broad-spectrum antiviral and immunomodulatory agent (COVID-19)
- SBIR Phase I: Novel Stereo-enriched Libraries as Commercial Complex Building Blocks for Facile Development of Biologically Active Compounds on Large Scale
Research funding history
4 SBIR/STTR records share this UEI (2018–2024). Reported award amounts total $2,430,995. Reported amounts are not federal obligations.
Phases: Phase II, Phase I
Agencies: National Science Foundation